Hey Daz, look at the bright side mate:
Not funding the vaccs anymore with possible indirect upside from the listing of the new company. Imagine funds raised from the intial IPO should keep the R&D going for the first few years.
As sobering the thought of funds to advance the TAVR R&D it will be interesting to see market reaction with postive updates/announcements on this and then, all well, interest from future partners.
I guess that leaves it up to the Adapt products/IP to carry the company meanwhile.
Lets see how the dust settles after June 30 th, interesting times.
Ann: MOU signed for Admedus Vaccines, page-75
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.27 |
Change
-0.880(7.24%) |
Mkt cap ! $251.5M | |||
| Open | High | Low | Value | Volume |
| $12.15 | $12.15 | $11.27 | $113.3K | 9.626K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 500 | $11.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.79 | 740 | 6 |
View Market Depth
| Last trade - 11.20am 07/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |